Search Results
ECHELON-1 AYA subgroup results: brentuximab vedotin plus AVD vs. ABVD
Dr. Younes on Brentuximab Plus AVD vs ABVD in Classical Hodgkin Lymphoma
Updated 3-Year Findings of ECHELON-1 Trial Presented for Classical Hodgkin Lymphoma
Real-world data on brentuximab vedotin with chemotherapy in Hodgkin lymphoma
Brentuximab vedotin: current status and future considerations for this agent in HL treatment
Dr. Flinn on FDA Approval of Frontline Brentuximab Vedotin With AVD in Hodgkin Lymphoma
Bretuximab vedotin plus re-induction chemotherapy for CD30+ R/R AML
Dr. Rizvi on the Limitations of ABVD in Hodgkin Lymphoma
New insights into the Treatment of Hodgkin Lymphoma
New advances in Hodgkin's Lymphoma - Jonathan Friedberg (USA) - (11-12 Feb2022)
Dr Anas Younes (Abstract S793)
Update on Hodgkin Lymphoma | LRF Webinars
